Verona Pharma plc (NASDAQ:VRNA) is a top growth stock with a raised price target of $110 by Jefferies analysts due to the success of COPD treatment Ohtuvayre. Sales are growing rapidly, projecting peak sales of $3-5 billion.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing